DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
DBV Technologies (Nasdaq:DBVT) announced the provisional appointment of Philina Lee, Ph.D. to its Board of Directors, effective October 30, 2025. She replaces Daniel Soland and will serve on the Board's Compensation Committee, increasing the Board to ten directors. The appointment is provisional and subject to shareholder ratification at the next annual meeting. Dr. Lee joins from Blueprint Medicines, where she led commercial operations including the launch and growth of AYVAKIT, and previously served on Fusion Pharmaceuticals' Board committees. DBV said her commercial and product-launch experience is expected to support advancement toward potential commercialization of VIASKIN Peanut for children and toddlers.
DBV Technologies (Nasdaq:DBVT) ha annunciato la nomina provvisoria di Philina Lee, Ph.D. nel Consiglio di Amministrazione, con effetto 30 ottobre 2025. Sostituisce Daniel Soland e farà parte del Comitato Compensazioni del Consiglio, portando il numero dei membri a dieci. La nomina è provvisoria e subordinata all'approvazione degli azionisti al prossimo assemblea annuale. La Dr.ssa Lee arriva da Blueprint Medicines, dove ha guidato le operazioni commerciali, incluso il lancio e la crescita di AYVAKIT, e in precedenza ha fatto parte dei comitati del Consiglio di Fusion Pharmaceuticals. DBV ha detto che la sua esperienza commerciale e nel lancio di prodotti è attesa per supportare l'avanzamento verso una possibile commercializzazione di VIASKIN Peanut per bambini e neonati.
DBV Technologies (Nasdaq:DBVT) anunció el nombramiento provisional de Philina Lee, Ph.D. en su Junta Directiva, con efecto a partir del 30 de octubre de 2025. Reemplaza a Daniel Soland y formará parte del Comité de Compensación de la Junta, aumentando el número de directores a diez. El nombramiento es provisional y sujeto a la ratificación de los accionistas en la próxima reunión anual. La Dra. Lee se incorpora desde Blueprint Medicines, donde lideró operaciones comerciales, incluido el lanzamiento y crecimiento de AYVAKIT, y previamente formó parte de comités de la Junta de Fusion Pharmaceuticals. DBV afirmó que su experiencia comercial y de lanzamiento de productos es susceptible de respaldar avances hacia una posible comercialización de VIASKIN Peanut para niños y bebés.
DBV Technologies (나스닥:DBVT)가 이사회에 필리나 리 박사의 잠정 임명을 발표했으며, 효력은 2025년 10월 30일부터입니다. 그녀는 다니엘 솔랜드를 대신해 이사회 보상위원회에 합류하여 이사회 구성원을 10명으로 늘립니다. 이 임명은 잠정적이며 주주 승인을 요하는 연례총회에서의 비준 여부에 달려 있습니다. 리 박사는 Blueprint Medicines에서 합류하여 AYVAKIT의 출시 및 성장 등 상업 운영을 이끌었고, 이전에는 Fusion Pharmaceuticals 이사회 위원회에서 일했습니다. DBV는 그녀의 상업적 경험과 제품 출시 경험이 아동용 VIASKIN Peanut의 상업화 가능성에 대한 진전을 지원하는 데 도움이 될 것으로 기대한다고 밝혔습니다.
DBV Technologies (Nasdaq:DBVT) a annoncé la nomination provisoire de Philina Lee, Ph.D. au conseil d'administration, effective le 30 octobre 2025. Elle remplace Daniel Soland et siégera au Comité de rémunération du conseil, portant le nombre de membres à dix. La nomination est provisoire et soumise à la ratification des actionnaires lors de la prochaine assemblée annuelle. La Dre Lee rejoint Blueprint Medicines, où elle a dirigé les opérations commerciales, y compris le lancement et la croissance de AYVAKIT, et a auparavant siégé dans des comités du conseil de Fusion Pharmaceuticals. DBV a déclaré que son expérience commerciale et de lancement de produits devrait soutenir les progrès vers une éventuelle commercialisation de VIASKIN Peanut pour les enfants et les tout-petits.
DBV Technologies (Nasdaq:DBVT) hat die vorläufige Ernennung von Philina Lee, Ph.D. in den Vorstand bekannt gegeben, wirksam ab dem 30. Oktober 2025. Sie ersetzt Daniel Soland und wird dem Vergütungsausschuss des Vorstands angehören, wodurch der Vorstand auf zehn Direktoren anwächst. Die Ernennung ist vorläufig und vorbehaltlich der Zustimmung der Aktionäre bei der nächsten Hauptversammlung. Dr. Lee kommt von Blueprint Medicines, wo sie die kommerziellen Abläufe geleitet hat, einschließlich des Starts und des Wachstums von AYVAKIT, und zuvor in Ausschüssen des Vorstands von Fusion Pharmaceuticals tätig war. DBV sagte, dass ihre kommerzielle Erfahrung und Produkt-Lancierungserfahrung voraussichtlich dazu beitragen wird, Fortschritte in Richtung einer potenziellen Kommerzialisierung von VIASKIN Peanut für Kinder und Kleinkinder zu unterstützen.
أعلنت شركة DBV Technologies (نازدك: DBVT) عن تعيين مؤقت لـ فيليانا لي، دكتوراه في مجلس إدارتها، فاعل اعتباراً من 30 أكتوبر 2025. هي تحل محل Daniel Soland وستعمل في لجنة التعويضات بالمجلس، مما يزيد عدد أعضاء المجلس إلى عشرة. التعيين مؤقت وخاضع لمصادقة المساهمين في الاجتماع السنوي القادم. تنضم الدكتورة لي من Blueprint Medicines، حيث قادت العمليات التجارية بما في ذلك الإطلاق والنمو لـ AYVAKIT، وكانت قد خدمت سابقاً في لجان مجلس Fusion Pharmaceuticals. قالت DBV إن خبرتها التجارية وخبرة إطلاق المنتجات من المتوقع أن تدعم التقدم نحو احتمال التسويق لـ VIASKIN Peanut للأطفال والرضع.
- Appointment effective October 30, 2025
- Board size increased to 10 directors
- Adds commercial launch experience from Blueprint Medicines
- New member will join the Compensation Committee
- Appointment is provisional and subject to shareholder ratification
- Dr. Lee replaces Daniel Soland, creating immediate board turnover
Châtillon, France, October 30, 2025
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the “Board”), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by the Company’s shareholders at the next annual meeting of shareholders. Dr. Lee will also serve as a member of the Compensation Committee of the Board. With this addition, the Company’s Board comprises ten directors.
"We are pleased to welcome Philina Lee as a new independent director to the Board," said Michel de Rosen, Chairman of the Board. "Philina’s extensive experience building successful biopharmaceutical organizations and commercializing pharmaceutical products will add tremendous value as the Company moves closer to potential commercialization.”
Dr. Lee joins DBV following a distinguished tenure at Blueprint Medicines where she progressed through increasingly senior roles, culminating in her leadership of the company's commercial organization as Chief Commercial Officer, overseeing the successful launch and growth of AYVAKIT®. She previously was on the Board of Directors at Fusion Pharmaceuticals, where she served on both the Nomination and Governance Committee and the Research and Development Committee.
"I am honored to join DBV’s Board at such a pivotal time for the Company, as it continues to advance VIASKIN® Peanut for children and toddlers with peanut allergy," said Dr. Lee. "I look forward to serving on the Compensation Committee and contributing to DBV’s growth and success."
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
VIASKIN is a registered trademark of DBV Technologies.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
FAQ
Who is Philina Lee and what role did DBV announce on October 30, 2025 for DBVT?
Is Philina Lee's DBVT board appointment final or subject to approval?
What committee will Philina Lee join on DBV's Board (DBVT)?
Which experience does Philina Lee bring to DBV that could affect DBVT shareholders?
Who does Philina Lee replace on DBV's board and how many directors will DBV have after the appointment?
How might Philina Lee's appointment relate to VIASKIN Peanut development for DBVT?
